AZD7442 PROVENT Phase III prophylaxis trial met primary endpoint in preventing COVID-19 3 years ago [#item_full_content] AZD1222 US Phase III Trial Met Primary Efficacy Endpoint in Preventing COVID-19 at Interim AnalysisDateMarch 22, 2021In relation toSimilar postNew Analyses of Two AZD7442 COVID-19 Phase III Trials in High-Risk Populations Confirm Robust Efficacy and Long-Term PreventionDateNovember 18, 2021In relation toSimilar postEVUSHELD (formerly AZD7442) long-acting antibody combination authorized for emergency use in the US for pre-exposure prophylaxis (prevention) of COVID-19DateDecember 9, 2021In relation toSimilar post
